Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Catalyst Pharma (CPRX) Stock Price & Analysis
1,970 Followers
CPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.09 - $17.67
Previous Close$14.72
Volume1.78M
Average Volume (3M)1.33M
Market Cap
$1.73B
Enterprise Value$1.60B
Total Cash (Recent Filing)$137.64M
Total Debt (Recent Filing)$3.19M
Price to Earnings (P/E)24.2
Beta1.01
Next Earnings
Aug 07, 2024EPS Estimate
$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding117,863,258
10 Day Avg. Volume988,820
30 Day Avg. Volume1,326,435
Standard Deviation0.16
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)9.21
Price to Sales (P/S)4.36
Price to Cash Flow (P/CF)8.00
P/FCF Ratio8.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit4.62
Enterprise Value/Ebitda12.56
Forecast
1Y Price Target
$27.17Price Target Upside73.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Catalyst Pharma News
Ownership Overview
13.79% Insiders
15.73% Mutual Funds
30.75% Other Institutional Investors
39.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $11.09 and its highest was $17.66 in the past 12 months.
What is Catalyst Pharma’s market cap?
Currently, no data Available
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Aug 07, 2024 which is in 89 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on May 08, 2024. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.198 by -$0.008.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is $0.28.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 117,863,260 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.19 in its last earnings report, missing expectations of $0.198. Following the earnings report the stock price went up 6.318%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Among the largest hedge funds holding Catalyst Pharma’s share is Deerfield Management Company, LP. It holds Catalyst Pharma’s shares valued at 149M.
---
Catalyst Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.17 (73.61% Upside)
$27.17 (73.61% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 909.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $702.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.25%
12-Months-Change
Fundamentals
Return on Equity
20.75%
Trailing 12-Months
Asset Growth
25.18%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
---
CPRX Earnings Call
Q4 2024
0:00 / 0:00
---
CPRX Stock 12 Month Forecast
Average Price Target
$27.17
▲(73.61% Upside)
Technical Analysis
Intra-Cellular Therapies
―
Ultragenyx Pharmaceutical
―
Anika Therapeutics
―
Protagonist Therapeutics
―
Best Analysts Covering CPRX
1 Year
1 Year Success Rate
14/19 ratings generated profit
1 Year Average Return
+22.23%
reiterated a buy rating 2 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +22.23% per trade.
---